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Health Related Quality of Life (HRQoL) has become an important
endpoint in cancer clinical trials (de Haes and van Knippenberg,
1985; Fayers and Machin, 1995) and a general review, including 
a survey of which measures are used in practice, has been made 
by Campbell et al (2000). HRQoL is particularly valuable in
assessing palliative treatments in situations where the size of any
survival advantage for a new treatment is, at most, modest. Thus,
there is a need to quantify the benefit of certain medical inter-
ventions in terms of a difference in HRQoL score rather than by
improvement in survival alone.
The sample size required for a clinical trial is critically depen-
dent on the pre-specified Type I error rate a, the pre-specified
Type II error rate b (which gives the power, defined as 1-b), and
the anticipated clinically meaningful difference in HRQoL score
(effect size), which are all interlinked (Machin et al, 1997). Since
HRQoL scales form ordered categories by definition, sometimes
they are far from appearing Normal in form and neither can they
be transformed into being approximately so. Often these measures
are subject to ‘floor’ or ‘ceiling’ effects in which the lowest or
highest category predominates.
In this paper, using data on HRQoL outcome scores from lung
cancer patients in a clinical trial, we demonstrate how the asym-
metric distribution of the measure has an important impact on 
the sample size calculations. We provide a comparison of two
methods of estimating sample sizes, one under the assumption of
normality and one that is distribution-free. We illustrate how
markedly different sample sizes are obtained and that one could
either under or over recruit patients to a trial depending on the
direction of the treatment effect. Also highlighted is how one
solution often applied to calculate sample sizes for non-normal
data, which is to dichotomize around a known cut-point, may
substantially overestimate the required sample size.
MATERIALS AND METHODS
The data
The data in this paper are taken from a randomized parallel group
controlled trial of a standard treatment against a less intensive
treatment in 310 patients with small-cell lung cancer and poor
prognosis (Medical Research Council Lung Cancer Working
Party, 1996). The standard treatment (A) consisted of a four-
drug regime (etoposide, cyclophosphamide, methotrexate and
vincristine) while the new less intensive treatment (B) under
investigation contained just two of these compounds (etoposide
and vincristine). The two treatment schedules were the same,
comprising three cycles of chemotherapy at the same dosage. Each
cycle was given on three consecutive days at three-week intervals.
The HRQoL questionnaires
The two HRQoL questionnaires used in this trial were the Hospital
Anxiety and Depression Scale (HADS) (Zigmond and Snaith,
1983) and the Rotterdam Symptom Checklist (RSCL) (de Haes et
al, 1990)
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doi: 10.1054/ bjoc.2000.1383, available online at http://www.idealibrary.com on The HADS provides scores in the range 0–21 in two dimen-
sions: anxiety and depression. It is a self-rating questionnaire
completed while patients wait to see a doctor and was developed
for use in a general outpatient setting. Moorey et al (1991)
reported that HADS is a useful instrument for measuring these
dimensions in cancer patients. The HADS has three clinically pre-
defined categories for each dimension: a total score 0–7 is defined
as a ‘normal’, 8–10 as a ‘borderline-case’ and 11–21 as a ‘case’
suggesting significant anxiety or depression.
The RSCL has two main scales, physical symptom distress and
psychological distress, in addition to the scales for activity and
overall evaluation. It was developed to measure the symptoms of
cancer patients participating in clinical research. Patients indicate
how much they have experienced particular symptoms over the
last week. The RSCL psychological dimension, for example, has
scores ranging from 0 to 24, where high scores constitute psycho-
logical distress. It has two clinically pre-defined categories where
a total score of 0–10 is considered a ‘non-case’ and 11–24 is a
‘case’ considered to constitute psychological distress.
In the trial setting both HRQoL questionnaires were completed
together and the 310 patients’ baseline scores prior to randomiza-
tion are used in this paper for expository purposes.
Sample size methodology
In the following, N is the total number of patients required in the
trial for a pre-specified Type I error rate, a, and power, 1-b, where
power is the probability of rejecting the null hypothesis given that
it is false. Z1-a/2 and Z1-b are the appropriate values from the stan-
dard Normal distribution for the 100 (1-a/2)% and 100 (1-b)%
percentiles respectively. Maximum power for a fixed number of
patients is achieved by dividing N into equal numbers of subjects
in each treatment group.
Normal distribution method
Assuming that the data have a Normal distribution, then the
sample size required to compare two means mA and mB, for a given
effect size d = mA – mB is given by Machin et al (1997) as:
Here, the standardized difference is d = d/s, where s is the true
standard deviation of the scores. The main factor in determining
sample size is this effect size. This is simply the size of the differ-
ence between treatments that is worth finding and it has been
referred to as the ‘clinically relevant’ difference. It is an important
point to note that the sample size obtained from equation (1) is the
same for both + d and for –d, that is, whether the patients get better
or get worse with respect to HRQoL with the new treatment. In
contrast, for a strongly skewed distribution, it does effect the
sample size if the score is anticipated to be decreased rather than
increased (Julious et al, 1995, 1997; Campbell et al, 1996).
Ordered categorical method
Most HRQoL scales have categories that can be ordered, but the
scores should not be treated as meaningful numbers, for example,
a change in HADS from 5 to 10 is not the same as a change from
10 to 15. However, methods have been developed for sample size
calculations for ordered categorical (ordinal) data (Whitehead,
1993).
Equation (2) is based on the Mann-Whitney U-test for ordered
categorical data. It estimates the sample size based on the odds
ratio (OR) of a patient being in a given category or less in one
treatment group compared to the other group. Here k is the number
of categories on the HRQoL instrument, p –
i is the mean proportion
expected in category i, that is, p –
i = (pAi + pBi)/2, where pAi and pBi
are the proportions anticipated in category i for the two treatment
groups A and B respectively.
The anticipated effect size is expressed as an odds ratio defined
as:
This is a measure which is not immediately straightforward to
interpret. Suppose in a clinical setting that with treatment A there
is an odds of 4:1 of a HADS Anxiety clinical case (the event of
interest), then this implies that for every 5 patients on treatment we
would expect 1 of them to be a clinical case. If however on B the
odds were lengthened to 8:1, then one would have an OR
=(4/1)/(8/1)= 0.50 in favour of B. In general, an OR should not be
interpreted as though it were a relative risk (RR). Using the same
example, 20.0% (1/5) of patients are clinical cases on A, whereas
11.1% (1/9) are with B, giving a relative risk, RR = 11.1/20.0 =
0.56 in favour of B. This is close, but not equal, to the value of the
corresponding OR. However, as two such event rates lower the
960 SA Julious et al
British Journal of Cancer (2000) 83(7), 959–963 © 2000 Cancer Research Campaign
N = 
4(Z1-a/2 + Z1-b)2
+ Z2
1-a/2
. (1)
d2 2
OR =
pAi(1–pBi)
pBi(1–pAi)
N = 
12(Z1–a/2 + Z1–b)2/(log OR )2
(2)
[1 –S
k
i=1
p –]
3
Table 1 Frequency of responses on the HADS Anxiety scores at baseline
for patients with small-cell lung cancer (data from Medical Research Council
Lung Cancer Working Party, 1996)
Category Score Number of
patients
Normal 0 0
10
21
30
42
53
65
71 0
Borderline 8 12
91 5
10 24
Clinical case 11 41
12 49
13 36
14 23
15 34
16 9
17 2
18 0
19 0
20 0
21 0
Total 266
Normal 0–7 21 (7.9%)
Borderline 8–10 51 (19.2%)
Clinical case 11–21 194 (72.9%)
Mean 11.70
SD (s) 2.66
Median 12odds ratio and the relative risk become closer and closer in
numerical value.
When designing a clinical trial, to estimate the odds ratio one
can utilise the predefined clinical cut points that the HADS and
RSCL each provide. For example, 27.1% of patients are defined
non-clinical cases on the HADS Anxiety dimension score at base-
line (see Table 1), that is, 27.1% record values resulting in a score
of ≤10. This we will take, for planning purposes, as what we would
expect on standard therapy (S). The odds with S is thus 0.271/
(1 – 0.271) = 0.372. Suppose a new therapy (T) is to be studied and
the investigator decided that a clinically meaning effect is one that
would increase the proportion of non-cases by 10%, that is, from
27.1 to 37.1% or a postulated odds of 0.371/(1 – 0.371) = 0.590.
The ratio of these odds gives OR = 0.372/0.590 = 0.63 in favour of
T. This value can then be used as the basis for the sample size
calculation.
Equation (2) makes no assumption about the distribution of the
data, but it does assume proportional odds between the treatments
across the HRQoL dimension. This implies that the odds ratios are
identical for each pair of adjacent categories throughout the scale.
What this means practically can be highlighted by extending the
example given above. When using the pre-defined clinical cut
point for ‘non-cases’ the investigator anticipated the OR would be
0.63. The assumption of proportional odds implies that, if instead
of using ≤10 as the definition of a ‘non-case’, ≤9 had been used,
one would nevertheless obtain OR9 = 0.63; and so on for OR8, OR7,
etc. Thus, although the actual observed odds ratios might differ
from each other across the scale, the corresponding population
values are all equal which implies that OR1 = OR2 = OR3 = … =
OR21 = 0.63. However, the calculations of sample size using equa-
tion (2) are robust to departures from this ideal, provided all the
odds ratios indicate an advantage to the same treatment.
RESULTS
Distributions
Figure 1 displays the distribution of the HADS anxiety scores at
baseline. It is negatively skewed. Figure 2 shows the equivalent
distribution of the RSCL psychological dimension scores. It is
positively skewed. In either case the scores do not have even
approximately the Normal distribution form. It therefore seems
that the usual mean and standard deviation are not adequate to
summarize the distributions. As a consequence, distribution-free
techniques should be used for testing treatment differences.
Comparison of methods
For expository purposes the HADS Anxiety scores at baseline,
given in Table 1, will be taken as the scores we anticipate for
patients on standard therapy (S). We further assume that we are
planning a randomized trial where we wish to demonstrate the
benefit of a new therapy (T) against this standard.
For purposes of calculating sample sizes we make an assump-
tion that the differences of interest range from –3 to +3 from the
population mean (or median) of S. In each example, the sample
sizes are calculated taking a two-sided significance level of 5%
and 80% power.
Normal distribution method
From Table 1 the anticipated mean score for the HADS Anxiety
scores for patients on S is 11.7 and thus a difference of 1 unit of
HRQoL would be for T to reduce this mean score to 10.7. The
anticipated standardized difference of interest is then, d = (mA –
mB)/s = (11.7 – 10.7)/2.66 = +0.376. Using equation (1), the
required sample size is estimated as N = 224 patients. If however,
we suspected that T would increase the mean HADS Anxiety score
rather than decrease it, then the corresponding standardized differ-
ence becomes d = (11.7 – 12.7)/2.66 = –0.376. From equation (1)
the sample size is again N = 224 patients. The results for various
anticipated difference in HADS anxiety scores are summarized in
the corresponding row of Table 2. It is thus evident that the
methodology, which assumes a symmetric (Normal) distribution
for the resulting data for the corresponding HRQoL dimension,
gives symmetric sample sizes. Thus the sample size obtained
depends only on the absolute value of the anticipated standardized
difference between treatments.
Ordered categorical method
For ordered categorical data, it is usually more informative to
describe the results in terms of the median rather than the mean.
Health related quality of life in cancer trials 961
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Table 2 Sample size estimates by the Normal distribution assumption and ordered categorical approach for a two treatment parallel group clinical trial for
specified anticipated difference between treatments on the HADS Anxiety score (two-sided, a = 5% and power, 1-b = 80%)
Anticipated difference
Method –3 –2 –1 +1 +2 +3
Normal 28a 58 224 224 58 28
Ordered categorical 42 98 1048 96 40 10
a In practice all these will be rounded upwards, to 30, 60, 230, etc.
HADS Anxiety Score at Baseline
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Figure 1 Distribution of HADS anxiety scores at baseline (data from
Medical Research Council Lung Cancer Working Party, 1996)Thus the median score for S is 12 (Table 1) and sample sizes can
therefore be derived for the situations where the anticipated
median on T is either reduced or increased. The calculations in the
worked example of Table 3 are for a reduction in the median score
to 11.
The first two columns of Table 3 gives the proportion and cumu-
lative proportions anticipated for each possible score of the HADS
Anxiety dimension and are based on those from the data given in
Table 1. Thus 60.9% of patients receiving S are anticipated in the
median score category 12 or less. The median score on T would
therefore be reduced by one unit at least, and the clinical problems
eased, if half (50%) or more of the patients on that treatment fell
into score category ≤11. As 42.5% of patients receiving S are
anticipated to be ≤11, the anticipated odds ratio for sample size
calculation purposes is determined as OR = (0.500 ´ 0.425)/
(0.575 ´ 0.500) = 0.739.
With this odds-ratio, and the proportions anticipated on S, the
anticipated cumulative proportions lying in each successive score
cell for T can be derived from QTi = QSi/[QSi + OR (1 – QSi)], where
QSi is the cumulative proportion in category i for treatment S.
Thus, for example, the anticipated proportion for score category
10 is QT10 = QS10/[QS10 + OR(1 – QS10)] = 0.271/[0.271 + 0.739(1 –
0.271)] = 0.335. Similarly, the cumulative proportions can be
calculated for the other categories and, from these, the anticipated
proportions derived and the final two columns in Table 3
completed. The mean proportion for each of the k = 15 categories
can now be estimated by: – p0–3 = (0.004 + 0.005)/2 = 0.005,
– p4 = (0.008 + 0.011)/2 = 0.010, – p5 = 0.013, – p6 = 0.022, …,
– p17–21 = 0.007. The sample size can now be calculated using
equation (2), which gives N = 1048.
These calculations were applied to the range of differences and
the results are summarized in the final row of Table 2. It is there-
fore evident that using equation (2) leads to asymmetric sample
sizes: the size depending on the sign of the difference.
The application of proportional odds therefore allows that, if the
distribution of one of the treatment groups can be specified, then
the anticipated cumulative proportions for the other treatment can
be directly derived. Hence, with prior knowledge of the distribu-
tion of just one treatment group and an anticipated OR, obtained
about any cut point on the HRQoL scale, an estimate of the sample
size can be obtained.
Number of categories
Despite the presence of a full ordered categorical scale,
researchers often estimate sample size and analyse studies, using
an odds ratio determined from a pre-defined score determining a
case and thereby ignore the other points on the HRQoL scale. For
example, with the HADS Anxiety dimension they simply classify
subjects as either a case or non-case. In this now binary data situ-
ation, equation (2) can still be used to estimate sample sizes but
ignoring the full ordered categorical nature of the data, may result
in a substantial over-estimate of the necessary trial size. For
example, if a clinically meaningful difference was set as an
increase in the number of subjects that are non-cases on the HADS
Anxiety score from 27.1% to 40.0% then this equates to an
962 SA Julious et al
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Table 3 Anticipated percentages of responses on the HADS Anxiety scores for standard treatment (S) and new treatment (T) for patients with small-cell lung
cancer (data from Medical Research Council Lung Cancer Working Party, 1996)
Standard therapy (S) New therapy (T)
Category Scorea Percentage Cumulative Percentage Cumulative
(PSi) percentage (pTi) percentage
(QSi)( QTi)
Normal 0–3 0.4 0.4 0.5 0.5
4 0.8 1.2 1.1 1.6
5 1.1 2.3 1.5 3.1
6 1.9 4.2 2.5 5.6
7 3.8 8.0 4.9 10.5
Borderline 8 4.5 12.5 5.7 16.2
9 5.6 18.1 6.8 23.0
10 9.0 27.1 10.0 33.5
Clinical case 11 15.4 42.5 16.5 50.0
12 18.4 60.9 17.8 67.8
13 13.5 74.4 11.9 79.7
14 8.6 83.0 7.1 86.9
15 12.8 95.8 10.0 96.9
16 3.4 99.2 2.5 99.4
17–21 0.8 100.0 0.6 100.0
a The 22 categories of Table 1 are reduced to k = 15.
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Figure 2 Distribution of RSCL psychological distress scores at baseline
(data from Medical Research Council Lung Cancer Working Party, 1996)OR = (0.271/0.729)/(0.400/0.600) = 0.58. Using this in equation
(2) gives N2 = 414 compared to only 282 using all k = 15 categories
in the calculations. This is an over-estimate of 47% in the neces-
sary sample size.
However, it may not be essential to use the full categorical scale.
For example, with HADS there is an additional category of
‘normal’ for subjects with a score of ≤8 and just under 8% of
patients are classified as such on the anxiety dimension (Table 2
and 3). If one then calculated the sample size using the k = 3
groups of ‘normal’, ‘borderline-case’ and ‘clinical-case’ as the
categories the estimated sample size is N3 = 400 subjects – only a
marginally closer estimate. However, if one identified an addi-
tional category of ‘severe-clinical-case’ for subjects with a HADS
score ³14 and based the sample size calculations on the 4 cate-
gories, the estimated sample size is N4 = 310 which is now quite
close to the optimal 282. Thus, only a modest increase in the
complexity of the calculations can lead to substantially better
estimates – choosing not more than k = 5 categories is usually
sufficient.
Choosing an effect size
Probably the most important component in the estimation of the
sample size is the effect size. If one halves this one quadruples the
sample size (Fayers and Machin, 1995). However, for HRQoL
measures this is often the component in the calculations which one
finds the most difficult to determine. Usually one can make an
intelligent guess at treatment difference from clinical experience
and from previously published work. However this experience has
yet to be gained for much HRQoL work in many contexts (see
however Fayers and Machin, 2000).
An advantage of the HADS and RSCL instruments for the
process of anticipating the effect size is that they both have prede-
fined definitions of what constitutes a ‘case’ and which can then be
used to obtain a value of a readily interpretable effect size. This
effect size, here expressed as an odds ratio, can thus be extended
across the full HRQoL scale and an estimate of the sample size
made.
DISCUSSION
The scores resulting from the two questionnaires highlighted
clearly do not have a normal distribution form. We have shown
that asymmetric distributions require different sample size esti-
mates depending on the direction of the effect size. Thus, as many
HRQoL measures do not take a Normal form, the sample size esti-
mates depend on the sign of d, and it is not appropriate to estimate
sample sizes under the Normal assumptions of equation (1).
Further the assumption of Normality can lead to unrealistically
sized trials which can be either under or over estimates of the size
actually required. Our recommendation is to use the distribution-free
equation (2) for sample size estimation when involving HRQoL as
an outcome measure in clinical trials.
Dichotomizing the HRQoL scale in order to estimate a sample
size (and consequently to analyse the subsequent data in the same
way) should be avoided if possible as sample sizes could be unnec-
essarily inflated. However, knowledge of anticipated responses in
only a handful of categories can give sample size estimates that are
more precise for only a modest increase in the complexity of the
calculations. We recommend therefore that when estimating
sample sizes associated with the use of HRQoL instruments in
clinical trials, the methods we have described should be used.
We also recommend that when reporting normative data for
HRQoL scores in different populations that the full frequency
distributions are given of the different dimensions. This informa-
tion would greatly facilitate the planning of future clinical trials.
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